Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
...tivity, in these models.
John Mayo, co-Managing General Partner of Celtic Pharma, said "This product has great steroid-sparing potential. The anti
tumor effects observed in preclinical studies also open up further valuable market opportunities."
XERECEPT(R) is an investigational new drug u...
Tackling Atrial Fibrillation and Associated Cardiovascular Risk
...explore dronedarone's rhythm and rate controlling properties
-- The ATHENA study is the first AF trial designed to evaluate the effect of an anti
arrhythmic drug (AAD) on morbidity and mortality. It showed that dronedarone (brand name Multaq(R)), a new AAD undergoing the registration pro...
Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
...facturers are seeking alternative
coatings for their products. Interface Biologics' Endexo(TM) anti-thrombic
additives are non-drug polymers that have anti
platelet properties. These
polymers are compatible with a wide range of base polymers, and since they
are an additive rather than a coating, afford ea...
Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
...d certified into the Banned
Substance Control Group's (BSCG) certification program. This is the only
certification program in the US that uses a World anti
accredited laboratory to detect for dangerous banned substances in
nutritional supplements. Each batch of Millennium's line of Surgex(TM...
38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
...llion people were mobilised at events involving faith groups and at the anti
Poverty fair. Campaigners called on the Arroyo government to change the...cy change directly to their politicians. -- In The Hague, the national anti
poverty campaign displayed 200 uniquely created life-size 'Avatars' whi...
ImClone Systems Showcases Extensive Research and Development
Program at the AACR Annual Meeting
...ies in novel combinations of biologic
-- IMC-A12 (anti-IGF-1R MAb) (#425 Burtrum et al., Abrogation of
PTEN does not confer resistance to anti
IGF-1R targeted therapy in
IGF responsive tumor cells ,#652 Prewett et al. IMC-A12 enhances
the efficacy of cetuximab and gemcitabine therapy in human...
Pharmexa A/S (DK) - Long lasting immune response and survival to
... June 4, 2007-Professor Trond Buanes today gave
a presentation titled "RAS peptide vaccination in resected
pancreatic cancer patients - persistence of anti
and long term survival" at ASCO's (American Society of Clinical
Oncology) annual cancer meeting.
A follow-up study of 23 resected pa...